Benznidazole, a drug employed in the treatment of Chagas' disease, down- regulates the synthesis of nitrite and cytokines by murine stimulated macrophages

Clinical and Experimental Immunology

Volumn 118, Issue 2, 1999, Pages 271-277

  Revelli, S ^c   Page, C Le ^a   Piaggio, E ^c   Wietzerbin, J ^a   Bottasso, Oscar ^b  

^a INSTITUT CURIE   (France)

^b FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^c NONE

Author keywords

Benznidazole; Cytokines; Down regulation; Inducible nitric oxide synthase; Nitrite

Indexed keywords

BENZNIDAZOLE; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NITRITE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CHAGAS DISEASE; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG ACTIVITY; DRUG MECHANISM; IMMUNOSTIMULATION; MACROPHAGE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; TRYPANOSOMA CRUZI;

ANIMALS; CELL LINE; CHAGAS DISEASE; CYTOKINES; DOWN-REGULATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; INTERLEUKIN-6; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; NITROIMIDAZOLES; TRYPANOSOMA CRUZI; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032749274     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1999.01053.x     Document Type: Article

References (34)

1. 1 Kirchof LV. American trypanosomiasis (Chagas' disease). A tropical disease now in the United States. N Engl J Med 1993; 329:639-44.
2. 2 Schmuñis GA. Trypanosoma cruzi, the etologic agent of Chagas' disease: status in the blood supply in endemic and nonendemic countries. Transfusion 1991; 31:547-57.
3. 3 Diaz de Toranzo EG, Castro JA, Franke de Cazzulo BM, Cazzulu JJ. Interaction of benznidazole reactive metabolites with nuclear and kinetoplastic DNA, proteins and lipids from Trypanosoma cruzi. Experientia 1988; 44:880-1.
4. 4 Do Campo R. Sensitivity of parasites to free radical damage by antiparasitic drugs. Chem Biol Interact 1990; 73:1-27.
5. 5 Marr JJ, Docampo R. Chemotherapy for Chagas' disease: a perspective of current therapy and considerations for future research. Rev Infect Dis 1986; 8:884-903.
6. 6 Gazzinelli RT, Oswald IP, Hieny S, James SL, Sher A. The microbicidal activity of interferon-γ-treated macrophages against Trypanosoma cruzi involves an 1.-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-β. Eur J Immunol 1992; 22:2501-6.
7. 7 Starobinas N, Russo M, Minoprio P, Honteyberie-Joskowicz M. Is TNFα involved in early susceptibility of Trypanosoma cruzi-infected C3H/He mice? Res Immunol 1991; 142:117-22.
8. 8 Black CM, Israelski DM, Suzuki Y, Remington JS. Effect of recombinant tumor necrosis factor on acute infection in mice with Toxoplasma gondii or Trypanosoma cruzi. Immunology 1989; 68:570-4.
9. 9 Truyens C, Angelo-Barrios A, Torrico F, Van Damme J, Heremans H, Carlier Y. Interleukin-6 (IL-6) production in mice infected with Trypanosoma cruzi: effect of its paradoxical increase by anti-IL-6 monoclonal antibody treatment on infection and acute-phase and humoral immune responses. Infect Immun 1994; 62:692-6.
10. 10 Silva JS, Morrisey PJ, Grabstein KH, Monler KM, Anderson D, Reed SG. Interleukin 10 and interferon gamma regulation in experimental Trypanosoma cruzi infection. J Exp Med 1992; 175:169-74.
11. 11 Revelli S, Didoli G, Roggero E, Moreno H, Bernabo J, Wietzerbin J, Bottasso O. Macrophage activity, IL-6 levels, antibody response and heart histology in rats undergoing an attenuated Trypanosoma cruzi acute infection upon treatment with recombinant interferon gamma. Cytokines, Cellular Mol Therapy 1998; 4:153-9.
12. 12 Tarleton RL. Trypanosoma cruzi-induced suppression of IL-2 production. I. Evidence for the presence of IL-2 producing cells. J Immunol 1988; 140:2763-8.
13. 13 Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43:119-25.
14. 14 Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992; 6:3051-64.
15. 15 Pellat-Deceunynck C, Wietzerbin J, Drapier JC. Nicotinamide inhibits nitric oxide synthase mRNA induction in activated macrophages. Biochem J 1994; 297:53-58.
16. 16 Drapier JC, Wietzerbin J, Hibbs JB Jr. IFN-γ and TNF-α induce the 1.-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol 1988; 18:1587-92.
17. 17 Vespa GNR, Cunha FQ, Silva JS. Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect Immun 1994; 62:5177-82.
18. 18 Petray P, Castaños-Velez E, Grinstein S, Örn A, Rottenberg ME. Role of nitric oxide in resistance and histopathology during experimental infection with Trypanosoma cruzi. Immunol Letters 1995; 47:121-6.
19. 19 Holscher C, Kohler G, Muller U, Mossman H, Schaub GU, Brombacher F. Defective nitric oxide effect or functions lead to extreme susceptibility of Trypanosoma cruzi-infceted mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Infect Immun 1998; 66:1208-15.
20. 20 Moreno SNJ, Docampo R, Mason RP, Leon W, Stoppani AOM. Different behaviors of benznidazole as free radical generator with mammalian and Trypanosoma cruzi preparations. Arch Biochem Biophys 1982; 218:585-91.
21. 21 Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd edn. Cold Spring Harbor: Cold Spring Harbor Laboratory, 1989.
22. 22 Lowenstein CJ, Alley ZX, Raval P, Snowman AM, Snyder SH, Russel SW, Murphy WJ. Macrophage NO synthase gene: two upstream regions mediate induction by IFN-γ and LPS. Proc Natl Acad Sci USA 1993; 90:9730-4.
23. 23 Morrison DC, Ryan JL. Endotoxin and disease mechanisms. Ann Rev Med 1987; 38:417-32.
24. 24 Masana M, de Toranzo EGD, Castro JA. Reductive metabolism and activation of benznidazole. Biochem Pharmacol 1984; 33:1041-5.
25. 25 Masana MI, de Toranzo EGD, Rubio MC, Castro JA. Effect of benznidazole on the mixed function oxygenase system from rat liver microsomes. Arch Int Pharmaco Ther 1985; 276:4-11.
26. 26 Gorla NB, Diaz Gomez MI, Castro JA. Interaction of benznidazole with DNA and nuclear proteins from rat liver. Arch Int Pharmacodyn Ther 1986; 280:22-31.
27. 27 Bogle RG, Whitley G St J, Soo S-C, Johnstone AP, Vallance P. Effect of anti-fungal imidazoles on mRNA levels and enzyme activity of inducible nitric oxide synthase. Br J Pharmacol 1994; 111:1257-61.
28. 28 Snick J. Ineterleukin-6: an overview. Ann Rev Immunol 1990; 8: 253-78.
29. 29 Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. Adv Immunol 1993; 54:1-78.
30. 30 Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-147.
31. 31 Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993; 54:167-227.
32. 32 Mosmann TR. Properties and functions of interleukin-10. Adv Immunol 1994; 56:1-26.
33. 33 Berg DJ, Kuhn R, Rajewsky K, Muller W, Menon S, Davidson N, Grunig G, Rennick D. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Schwartzman reaction but not endotoxin tolerance. J Clin Invest 1995; 96:2339-47.
34. 34 Jacobs F, Chaussabel D, Truyens C, Leclerq V, Carlier Y, Goldman M, Vray B. IL-10 up-regulates nitric oxide (NO) synthesis by lipopolysaccharide (LPS)-activated macrophages: improved control of Trypanosoma cruzi infection. Clin Exp Immunol 1998; 113:59-64.